Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Gao L, Gao GF. Yang S, et al. Among authors: hu z. Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24. Lancet Infect Dis. 2021. PMID: 33773111 Free PMC article. Clinical Trial.
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J, Satari HI, Khaliq T, Sughra U, Celi AP, Li F, Li Y, Jiang Z, Dalimova D, Tuychiev J, Turdikulova S, Ikram A, Flores Lastra N, Ding F, Suhardono M, Fadlyana E, Yan J, Hu Z, Li C, Abdurakhmonov IY, Gao GF; ZF2001 Global Trial Group. Dai L, et al. Among authors: hu z. N Engl J Med. 2022 Jun 2;386(22):2097-2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. N Engl J Med. 2022. PMID: 35507481 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults.
Luo D, Pan H, He P, Yang X, Li T, Ning N, Fang X, Yu W, Wei M, Gao H, Wang X, Gu H, Mei M, Li X, Zhang L, Li D, Gao C, Gao J, Fei G, Li Y, Yang Y, Xu Y, Wei W, Sun Y, Zhu F, Hu Z, Wang H. Luo D, et al. Among authors: hu z. Clin Transl Med. 2022 Sep;12(9):e1016. doi: 10.1002/ctm2.1016. Clin Transl Med. 2022. PMID: 36103390 Free PMC article. Clinical Trial.
Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L, Li Y, He P, Chen Z, Yang H, Li F, Zhang S, Wang D, Wang G, Yang S, Gong L, Ding F, Ling M, Wang X, Ci L, Dai L, Gao GF, Huang T, Hu Z, Ying Z, Sun J, Zuo X. Gao L, et al. Among authors: hu z. Lancet Child Adolesc Health. 2023 Apr;7(4):269-279. doi: 10.1016/S2352-4642(22)00376-5. Epub 2023 Feb 17. Lancet Child Adolesc Health. 2023. PMID: 36803632 Free PMC article. Clinical Trial.
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Sun S, He L, Zhao Z, Gu H, Fang X, Wang T, Yang X, Chen S, Deng Y, Li J, Zhao J, Li L, Li X, He P, Li G, Li H, Zhao Y, Gao C, Lang X, Wang X, Fei G, Li Y, Geng S, Gao Y, Wei W, Hu Z, Han G, Sun Y. Sun S, et al. Among authors: hu z. Cell Mol Immunol. 2021 Apr;18(4):1070-1073. doi: 10.1038/s41423-021-00658-z. Epub 2021 Mar 17. Cell Mol Immunol. 2021. PMID: 33731916 Free PMC article. No abstract available.
Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
Zhang J, Hu Z, He J, Liao Y, Li Y, Pei R, Fang X, Zeng P, Fan R, Ou Z, Deng J, Zhou J, Guan W, Min Y, Deng F, Peng H, Zhang Z, Feng C, Xin B. Zhang J, et al. Among authors: hu z. Emerg Microbes Infect. 2021 Dec;10(1):1589-1597. doi: 10.1080/22221751.2021.1951126. Emerg Microbes Infect. 2021. PMID: 34197281 Free PMC article. Clinical Trial.
Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
Shu YJ, He JF, Pei RJ, He P, Huang ZH, Chen SM, Ou ZQ, Deng JL, Zeng PY, Zhou J, Min YQ, Deng F, Peng H, Zhang Z, Wang B, Xu ZH, Guan WX, Hu ZY, Zhang JK. Shu YJ, et al. Among authors: hu zy. Chin Med J (Engl). 2021 Jul 22;134(16):1967-1976. doi: 10.1097/CM9.0000000000001702. Chin Med J (Engl). 2021. PMID: 34310400 Free PMC article. Clinical Trial.
20,402 results
You have reached the last available page of results. Please see the User Guide for more information.